LinkedIn image ad examples

Get agency-quality medical communications decks for overflow work and smaller projects, with AI + human experts at up to 50% lower cost. Explore Prezent.

Every new tender starts with documents you've already filled out dozens of times.

Revisit the key takeaways from our #MSToronto 2026 sessions. #RocheNeurology #MS

Access the latest data and session highlights on MS care now. #MSToronto 2026 #RocheNeurology #MS

Discover how dosing, safety, trial design and patient engagement must adapt for immunotherapy in chronic disease populations.

Chronic disease populations need a different approach to dosing, safety and trial design. Download the whitepaper to explore key strategies.

Picture your life in Australia Thinking about what your next chapter could look like? I-MED Radiology Network is visiting the UK this November to connect with radiologists interested in exploring career opportunities in Australia. From potential locations and working arrangements to registration pathways, we’d love to help you understand your options and what a move could look like for you. Meet us at the @BIR Annual Congress in Birmingham, or join us for dinner in Birmingham or London. 📍 BIR Annual Congress | 12–13 November 🍽️ Birmingham dinner | 12 November, 7pm 🍽️ London dinner | 14 November, 7pm Not attending BIR? You can still join us for dinner or request a virtual conversation. Book your chat here: https://lnkd.in/gVsNJMkK

Join us on Plasma Proteins Science Day to get the latest insights into the detection, monitoring, and discrimination of systemic amyloidosis.

Imaging is a journey, not a single step. From sites and image collection to quality control, readers and central review, every part of the workflow contributes to the data behind your clinical endpoints. Collective Minds connects the entire imaging journey in one centralized platform. Bring your imaging workflow together and keep your trial moving toward its endpoints.

Multiple trials shouldn’t mean multiple imaging workflows. Collective Minds connects image collections, QC, central review and reader workflows, giving CRO teams a more connected and centralized way to manage imaging in clinical trials. See how it works.

Strong tablets shouldn’t mean slow disintegration. Nutracore LFP helps manufacturers produce durable, low-friability tablets while supporting fast disintegration, smooth compression and easy ejection. Its reliable performance has been designed for today’s nutraceutical formulations.

Our new label-friendly lubricant is designed to simplify nutraceutical tablet and capsule manufacturing. Nutracore LFP supports improved flow, smooth compression, easy ejection and consistent quality—without the need for extra sifting or pre-blending. Discover a simpler way to manufacture nutraceutical tablets and capsules.

Join us on November 5, 2026, for the second webinar in our free series: The value of Automation – Practical application insights for smarter labs In this session we'll explore: Automating cell-based assays: from cell viability to potency Ismail Cisse, PhD, Field Support Scientist for High Throughput applications at Promega, will offer a practical look at what changes when cell-based assays move to an automated liquid handler. Using cell viability as a starting point, he'll explore how automation can support more consistent workflows and help reduce manual variability. He'll also look at the role of reproducibility in bioassays for biologics, where dose-response curves and relative potency measurements support release and stability testing. Why attend? • Understand which cell-based assay characteristics are well suited to automation. • Learn what to check when transferring an established manual protocol. • Explore how automation can support more consistent cell seeding, dilution, and reagent addition. • See how automated workflows can help reduce assay variability. • Discover where automation can add value first—from cell viability assays to potency testing. Leave with a clearer view of how to assess, transfer, and automate cell-based workflows with greater confidence 📅 November 5, 2026 | 4:00 p.m. CET Join us live and bring your questions about laboratory automation.

Aiforia® Breast Cancer Suite improves workflow efficiency and diagnostic accuracy in pathology labs. It consists of AI models and a matching Aiforia® Clinical Suite Viewer that support pathologists in the histological grading of breast cancer and in the assessment of breast cancer IHC markers. Request a demo to learn if it could optimize your current workflow. ⬇️

Aiforia® Breast Cancer Suite offers advanced tools for histological grading and biomarker detection, ensuring precision and efficiency. - Aiforia® Breast Cancer Grading - Aiforia® Breast Cancer Ki67 - Aiforia® Breast Cancer ER - Aiforia® Breast Cancer PR - Aiforia® Breast Cancer HER2 - Aiforia® Lymph Node Metastasis Take the next step to see how AI seamlessly integrates to enhance every step, from sample analysis to diagnosis. ⬇️

Distributing IVD products? Meet Calpro at MEDICA to discuss calprotectin testing in your market. Does your company distribute in vitro diagnostics? Calpro is meeting distribution companies at MEDICA in Düsseldorf, 16–19 November, to discuss calprotectin testing in new markets. Book a meeting in advance: https://lnkd.in/eyPDdxFe

What if every reimbursement decision could benefit from the experience of thousands of healthcare providers? Meet Aptarro Prism. Powered by intelligence from 500M+ annual transactions and reimbursement patterns across a network serving 130K+ providers, Prism helps your team identify opportunities, anticipate denials, and act at the point-of-decision.

Which markets need calprotectin testing? You know yours. Tell us about it at MEDICA. Your company knows its market: the laboratories, the clinicians and the tenders. We are meeting distributors at MEDICA in Düsseldorf, 16–19 November, to discuss calprotectin testing in new markets. https://lnkd.in/eyPDdxFe

The cost of not treating #dryeye may be greater than you think. Dry eye disease can affect more than the eyes, potentially impacting patients’ emotional wellbeing and everyday activities. Join eye care experts Drs. Laura M Periman, MD and Jackie Garlich, O.D., F.A.A.O for a LinkedIn Live discussion as they explore the often-overlooked impact of delayed care and why earlier recognition and appropriate intervention matter. 📅 November 17 ⏱️ 2:00 PM EST 📍 Bausch + Lomb LinkedIn Click “Register” to save your spot and receive event reminders: https://lnkd.in/gz_Drixm #SeeBetterLiveBetter #EyeHealth #Optometry #Ophthalmology #DED

Benchmark performance, uncover opportunities for improvement, and prioritize the decisions that matter most. Prism brings together reimbursement patterns, payer signals, and insights from across the Aptarro network to help your team see more, before it costs you a reimbursement.

We hear a version of the same question in almost every customer conversation and RFP: can we use generative AI in research workflows, and if so, how do we make sure the outputs pass regulatory scrutiny? The concern is legitimate. A peer-reviewed study published in JMIR Publications Mental Health in November 2025 found that nearly 20% of citations generated by GPT-4o in simulated literature reviews were fabricated, rising to 29% in less familiar or specialized topics. ISPOR—The Professional Society for Health Economics and Outcomes Research 's ELEVATE-GenAI framework, published in Value in Health in November 2025, sets out what HEOR teams need to document when LLMs play a substantive role in their evidence. It is already referenced in NiCE 's position statement on AI in HTA submissions, and CDA and G-BA are following suit. Organizations submitting HEOR evidence to these bodies will increasingly be expected to document AI use against its 10 domains. Every extraction must be traceable to its source document. Model version and update governance must be documented. Outputs must be reproducible from the same document, prompt, and model version. Confidence levels must be communicated. All AI activity must be logged. General-purpose LLMs used through a chat interface cannot meet these requirements. Their outputs are non-deterministic by design, and training data provenance is opaque. The variability and inference beyond the source that make them useful for open-ended tasks are the same properties that make them indefensible in a regulatory submission. This is a problem specific to general-purpose LLMs. Deterministic AI has been part of systematic review workflows for years, including our own. DistillerSR's Smart Evidence Extraction (SEE) was purpose-built for regulated evidence environments. Every extraction is source-cited, every model version is traceable, and every AI suggestion requires a human decision that is logged to the audit record. Customer data is never used to train third-party models. Our new white paper maps SEE against all 10 ELEVATE-GenAI domains and explains what that means in practice for teams preparing HTA submissions. Read the white paper: https://lnkd.in/gsWtnn8M

"AI-assisted workflows saved an estimated 7–9 hours of screening effort and reduced extraction time from 70+ manual hours to approximately one hour, without compromising data quality." What actually moves the needle on economic mobility? The evidence sits across housing, education, workforce development, health, and human services, each with its own terminology and its own way of measuring success. This was the task at hand for an internally funded RTI International research effort. Here is where RTI leveraged DistillerSR’s regulatory-grade AI to make the difference. ◾ One place for a fragmented evidence base. Records from academic and gray literature sources were imported, deduplicated, and managed in a single centralized workflow, with 397 references entering title and abstract review. ◾Human-in-the-loop screening by design. AI Rerank continuously surfaced the most promising papers for human review. That accounted for an estimated 7 to 9 hours of screening effort. ◾Data extraction measured in hours instead of weeks. Smart Evidence Extraction populated structured extraction forms directly from full text while keeping every field traceable to its source. At the team's observed manual pace, the 281 records processed would have taken 70 or more hours. With DistillerSR’s regulatory-grade AI, the recorded review time was about one hour. ◾Quality checks aimed at the hardest cases. Weighted kappa across reviewers and AI-assisted decisions was 0.93. The team then hand-checked a random sample of records with below-median AI confidence scores and found a single false inclusion, along with strong alignment between extracted fields and source documents. With the routine review work handled, the team put its time into thematic synthesis, cross-sector comparison, and building a theory-driven economic mobility framework that policy and program leaders can actually apply. Read the full case study https://bit.ly/4hafWxZ to see how RTI scaled a complex, cross-sector review without giving up rigour or reproducibility. A special thanks to Megan Lindstrom and Tatiana E. B. for sharing their journey with us.

How could a clearer understanding of nutritional needs help shape future treatment for patients in neuro-intensive care? This is what NeuroNutriTraj, the research project led by Dr. Stefano Marelli, sets out to explore. The project has been awarded the 2026 ESICM–Fresenius Kabi Medical Nutrition Grant today. The €20,000 grant will support his research project; exploring how patients’ nutritional needs may change throughout serious illness and recovery after a brain injury. By mapping nutritional status and responses over time, the project aims to generate insights that may inform future research into more personalized nutritional approaches – with the long-term goal of supporting care that better reflects each patient’s changing needs. As part of the Fresenius Group, supporting patients and healthcare professionals in advancing care through research in medical nutrition is one way we contribute to #FutureFresenius. #FreseniusCommittedToLife #FutureFresenius #LIVES2026

Luin eilen vanhusasiavaltuutetun raportin Kohti toimivampia sosiaali- ja terveyspalveluita iäkkäille - Kokonaiskuva ja ehdotuksia päätöksentekijöille. Raportissa oli todettu, että ikäihmisen matka palveluihin on kuoppainen. Raportissa on kuvattu muun muassa omaishoitajan haasteellista tilannetta case-esimerkillä. Kiitos Vanhusasiavaltuutettu valaisevasta raportista. Palasin lukukokemuksen jälkeen Pöllölaakson tunnelmiin. Olin Gunin kanssa kertomassa omaishoitajan arjesta. Gun omaishoitajuuden kokeneena ja minä sivusta seuranneena sote-ammattilaisena. Attendo Suomi kampanjassa Pitkä matka kotiin läheiset kertovat, että millaista on elää läheisen rinnalla kun hoivaan pääsy viivästyy. Matka kotiin on pitkä ja kuoppainen.